Viking Therapeutics/$VKTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Ticker
$VKTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
49
Website
VKTX Metrics
BasicAdvanced
$3.7B
-
-$1.54
0.62
-
Price and volume
Market cap
$3.7B
Beta
0.62
52-week high
$74.15
52-week low
$18.92
Average daily volume
4.1M
Financial strength
Current ratio
25.86
Quick ratio
25.257
Long term debt to equity
0.052
Total debt to equity
0.11
Interest coverage (TTM)
-2,217.05%
Profitability
Management effectiveness
Return on assets (TTM)
-14.99%
Return on equity (TTM)
-19.99%
Valuation
Price to book
4.69
Price to tangible book (TTM)
4.69
Price to free cash flow (TTM)
-24.296
Free cash flow yield (TTM)
-4.12%
Free cash flow per share (TTM)
-1.366
Growth
Earnings per share change (TTM)
64.31%
3-year earnings per share growth (CAGR)
26.33%
10-year earnings per share growth (CAGR)
-4.36%
What the Analysts think about VKTX
Analyst ratings (Buy, Hold, Sell) for Viking Therapeutics stock.
Bulls say / Bears say
Viking Therapeutics' VK2735 achieved a 14.7% reduction in body weight during its Phase 2 VENTURE study, surpassing expectations and indicating strong potential in the weight-loss market. (InvestorPlace)
The company has entered a multi-year strategic partnership with CordenPharma to ensure large-scale manufacturing capabilities for VK2735, supporting potential multi-billion-dollar annual product sales. (StockTitan)
Viking Therapeutics plans to advance VK2735 directly to Phase 3 trials, potentially accelerating its market entry by a year and positioning it as a strong competitor in the GLP-1 market. (Yahoo Finance)
Insider selling activity, including CEO Brian Lian's sale of 194,490 shares, may raise concerns about executives' confidence in the company's future prospects. (American Banking and Market News)
Viking Therapeutics faces intense competition from established players like Eli Lilly and Novo Nordisk in the GLP-1 market, which could challenge its market penetration and profitability. (Yahoo Finance)
The company's stock experienced a significant pullback after a nearly 300% increase in the prior quarter, indicating potential volatility and investor uncertainty. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
VKTX Financial Performance
Revenues and expenses
VKTX Earnings Performance
Company profitability
VKTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Viking Therapeutics stock?
Viking Therapeutics (VKTX) has a market cap of $3.7B as of July 29, 2025.
What is the P/E ratio for Viking Therapeutics stock?
The price to earnings (P/E) ratio for Viking Therapeutics (VKTX) stock is 0 as of July 29, 2025.
Does Viking Therapeutics stock pay dividends?
No, Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders as of July 29, 2025.
When is the next Viking Therapeutics dividend payment date?
Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Viking Therapeutics?
Viking Therapeutics (VKTX) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.